Nordic Life Science 1
PH A SE I I I THE COMPANY HAS ANNOUNCED POSITIVE
OVERALL SURVIVAL (OS) RESULTS FROM THE PHASE III CASPIAN TRIAL WITH IMFINZI IN 1ST-LINE EXTENSIVE-STAGE SMALL CELL LUNG CANCER (SCLC). A PLANNED INTERIM analysis conducted by an Independent Data Monitoring Committee concluded that the trial has met its primary endpoint by showing a statistically-significant and clinically-meaningful improvement in OS in patients treated with Imfinzi in combination with standard-of-care etoposide and platinum-based chemotherapy options vs. chemotherapy alone. The safety and tolerability for this Imfinzi combination was consistent with the known safety profiles of these medicines. “The Phase III CASPIAN results offer new hope for patients who are facing the devastating diagnosis of small cell lung cancer, and for whom new medicines are urgently needed. This is the first trial offering the flexibility of combining immunotherapy with different platinum-based regimens in small cell lung cancer, expanding treatment options,” says José Baselga, Executive Vice President, Oncology R&D, AstraZeneca.